ArticleBlood2016
Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation.
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- The Unexpected Protective Role of Thrombosis in Lung Injury via Endothelial Alox15.Circulation research · 2026Article
- Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review.Journal of clinical medicine · 2025Review
- Interplay of genetic and clinical factors in cancer-associated thrombosis: Deciphering the prothrombotic landscape of colorectal cancer.World journal of gastroenterology · 2025Review
- Plasma microRNA Environment Linked to Tissue Factor Pathway and Cancer-Associated Thrombosis: Prognostic Significance in Ovarian Cancer.Biomolecules · 2024Article
- Bioinformatics and Machine Learning-Based Identification of Critical Biomarkers and Immune Infiltration in Venous Thromboembolism.International journal of analytical chemistry · 2024Article
- Review
- Review
- Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach.Journal of thoracic disease · 2021Review
- MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer.Frontiers in cell and developmental biology · 2021Article
- [Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach].Archivos de bronconeumologia · 2021Review
- Surviving and thriving in thrombosis research during a global pandemic: Experiences of a vascular scientist diagnosed with COVID-19.Thrombosis update · 2021Article
- Catheter-directed thrombolysis to treat acute pulmonary thrombosis in a patient with COVID-19 pneumonia.BMJ case reports · 2020Article
- Endothelial cells and organ function: applications and implications of understanding unique and reciprocal remodelling.The FEBS journal · 2020Review
- YC-1 Prevents Tumor-Associated Tissue Factor Expression and Procoagulant Activity in Hypoxic Conditions by Inhibiting p38/NF-κB Signaling Pathway.International journal of molecular sciences · 2019Article
- Hypoxia and HIF activation as a possible link between sepsis and thrombosis.Thrombosis journal · 2019Article
- Sepsis-induced thrombus formation and cell-specific HIFs.Thrombosis research · 2018Article
- Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis.Biology open · 2017Article
- Target of obstructive sleep apnea syndrome merge lung cancer: based on big data platform.Oncotarget · 2017Article
- Anticoagulation, ferrotoxicity and the future of translational lung cancer research.Translational lung cancer research · 2016Review
- Clinical Characteristics and Risk Factors of Patients with Lung Cancer Complicated with Pulmonary Embolism: A Case Control Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Despite the increased risk of thrombosis in cancer patients compared with healthy individuals, mechanisms that regulate cancer-induced hypercoagulation are incompletely understood. The aim of this study was to investigate whether cell-specific hypoxia-inducible factor (HIF) 1α regulates cancer-associated hypercoagulation, using in vitro clotting assays and in vivo cancer models. In mouse lung and mammary tumor cells, hypoxia led to increases in cell adhesion, clotting, and fibrin deposition; these increases were eliminated in HIF1α null cells. Increased levels of HIF1α were also associated with increased tissue factor expression in human breast tumor samples. Conversely, deletion of endothelial (but not myeloid) cell-specific HIF1α doubled pulmonary fibrin deposition, and trebled thrombus formation compared with wildtype littermates in tumor-bearing mice. Our data suggest that tumor and endothelial cell-specific HIF1α may have opposing roles in cancer-associated coagulation and thrombosis. Off-target effects of manipulating the HIF1 axis in cancer patients should be carefully considered when managing thrombotic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.